Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New ANDA Review Pathways: Should You Be A Priority Or Expedited?

Executive Summary

Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.


Related Content

Will GDUFA III Curtail Priority Assessments?
Generic Review At US FDA: Record Month Completes Approval Volume Recovery
Competitive Generic Therapy Designations Growing Despite Lack Of Guidance
Goal Date Confusion: The Downside Of Generic Drug Assessment Transparency
ANDA Median Approval Times Still Rising, But What Does It Mean?
More ANDAs To Be Eligible For Priority Review, Gottlieb Says
ANDA Sponsors Get Wide-Open Facility Deadline For Priority Review
Breakthrough-Style Program For ANDAs Added To House User Fee Bill
Generic Priority Review Expanded In Senate User Fee Bill
“Breakthrough” Designation: FDA Clarifies How To Get It – And How It Can Be Lost


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts